Ophthalmology Therapeutics: Does current pipeline innovation hold the potential to affect the future ophthalmology market?

This Frontier Pharma: Ophthalmology Therapeutics assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products.

Pune, India - March 14, 2018 /MarketersMedia/ —

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs

Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
• Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
• Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get this report at: https://www.themarketreports.com/report/buy-now/935550

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935550

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/ophthalmology-therapeutics-does-current-pipeline-innovation-hold-the-potential-to-affect-the-future-ophthalmology-market/314326

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs%20%20

Source: MarketersMedia

Release ID: 314326

More Press Releases

Stocks, bond yields fall sharply as growth worries spread

Mar 23, 2019

Wall Street was roiled Friday by new signs that global economic growth is slowing. The jitters triggered a sell-off in stocks and sent bond yields sharply lower, flashing a possible recession warning. The wave of selling knocked 460 points off the Dow Jones Industrial Average and gave the benchmark S&P 500 index its worst day since Jan. 3. The Russell 2000 index of smaller company stocks fell more than the rest of the market as traders offloaded risker assets. Worried investors shifted money into bonds, which sent yields much lower. The yield on the 10-year Treasury dropped to 2.43 percent...

Markets Right Now: Stocks, yields drop on growth worries

Mar 23, 2019

NEW YORK — The latest on developments in financial markets (all times local): 4 p.m. Stocks closed broadly lower on Wall Street, erasing their gains for the week, as investors became increasingly worried that the global economy is slowing down. Traders shifted money into bonds and other low-risk assets Friday. Bond yields fell sharply, hurting bank stocks and flashing a possible recession warning. Citigroup slumped 4.6 percent. Boeing fell 2.8 percent after Indonesia's flag carrier said it would seek to cancel an order of the company's planes. The S&P 500 fell 54 points, or 1.9 percent, to 2,800. The Dow...

Trump to nominate conservative Stephen Moore for Fed board

Mar 23, 2019

WASHINGTON — President Donald Trump said Friday that he will nominate Stephen Moore, a conservative economic analyst and frequent critic of the Federal Reserve, to fill a vacancy on the Fed's seven-member board. Moore, a well-known and often polarizing figure in Washington political circles, served as an adviser to Trump during the 2016 campaign. In that role, he helped draft Trump's tax cut plan. Trump has been harshly critical of the Fed's rate increases even after the central bank announced this week that it foresees no hikes this year. Moore, formerly chief economist for the conservative Heritage Foundation, has also...

Italy, China deepen ties under wary gaze of US, EU

Mar 23, 2019

MILAN — Italy's head of state told visiting Chinese President Xi Jinping on Friday that China's new "Silk Road" linking Europe and Asia must be a "two-way street," addressing concerns among Western allies that the colossal infrastructure project is meant merely to amplify Beijing's global influence. During Xi's two-day official state visit, Italy is expected to become the first major democracy to sign an agreement to join China's "Belt and Road" initiative. The program aims to invest in ports, roads, airports and railways in Asia, Africa and Europe to create a conduit for trade and China's construction industry. Both the...

Stocks fall on growth worries, Brexit doubts

Mar 23, 2019

SINGAPORE — Stocks fell sharply in Europe on Friday after surveys showed manufacturing in the region slowed in March and amid news that the European Union offered only a brief extension to the Brexit deadline. U.S. markets also appeared headed for a lower open. Britain's FTSE 100 led the decline, trading down 1.3 percent at 7,260, while the CAC 40 in France slid 1.2 percent to 5,315. Germany's DAX lost 0.7 percent to 11,467. The future contract for the Dow Jones Industrial Average was 0.7 percent lower at 25,828. That for the broad S&P 500 index also lost 0.7 percent,...

Subscribe to our newsletter!

Your Name

Your Email Address